엔젠바이오

354200KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

52.5 / 100

Reference Date: 2026-04-13

Financial Score18.5 / 40

News Sentiment20.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 18.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

EnzenBio is a biotech company specializing in in vitro diagnostic medical devices and services using genomic analysis, liquid biopsy, and precision diagnostics. It leverages next-generation sequencing (NGS) and bioinformatics algorithms to detect mutations in cancer and genetic diseases, offering personalized treatment solutions.

Number of Employees

56people

Average Salary

61.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 59.134.0Point

PBR

1.99Industry Average 1.942.5Point

Higher than industry avg (caution)

ROE

-33.54Industry Average 1.530.0Point

Well below industry avg

Debt Ratio

7.51Industry Average 16.096.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲152.0% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲14.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -59.2% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 80

Positive
엔젠바이오, 가톨릭대·美 야티리바이오와 3자 MOU 체결…"MRD 극복...
엔젠바이오는 가톨릭대학교, 야티리바이오와 미세잔존질환(MRD) 정밀진단 기술 고도화를 위한 양해각서(MOU)를 체결하며 차세대 MRD 진단 체계 구축을 목표로 하고 있습니다.
Positive
엔젠바이오, 지난해 매출 212억원 기록…전년比 278% 급증
엔젠바이오는 지난해 매출액 212억 원을 기록하며 전년 대비 278% 급증했고, 영업손실도 34% 축소되는 등 손익구조 개선세가 뚜렷합니다.
Positive
엔젠바이오, 작년 매출 전년比 278% 성장…“수익성 개선 가시화”
엔젠바이오는 지난해 연결 기준 매출액이 212억 원으로 전년 대비 278.5% 증가했으며, 핵심 사업 성장과 자회사 편입 효과로 수익성 개선이 가시화되고 있습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 1,677Won52-week high 2,63552-week low 1,380

1-month return0.0Point

1m -18.39% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral정기주주총회결과2026-03-31
Neutral합병등종료보고서(합병)2026-03-31
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-31
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-31